منابع مشابه
Pharmacogenomic approach in type 2 diabetes treatment
Introduction: Type 2 diabetes (T2D) is chronic health caused by the interaction between genetic and environmental factors that results in high blood glucose. The evidence-based guidelines for diabetes management are mainly based on lifestyle changes, control of risk factors, and the management of blood glucose levels. Although numerous antidiabetic agents have been developed over time, T2D trea...
متن کاملOptimizing combination treatment in the management of type 2 diabetes
Obtaining the suggested glycemic control is the most important achievement in order to prevent cardiovascular complications in patients with type 2 diabetes. Monotherapy often fails after a period of treatment, so that multiple drugs are needed to achieve effective glycemic control. A number of oral glucose lowering drugs is now available such as metformin, sulfonylureas, non-sulfonylureas secr...
متن کاملInsulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
Glycemic control remains the major therapeutic objective to prevent or delay the onset and progression of complications related to diabetes mellitus. Insulin therapy represents a cornerstone in the treatment of diabetes and has been used widely for achieving glycemic goals. Nevertheless, a large portion of the population with diabetes does not meet the internationally agreed glycemic targets. M...
متن کاملTreatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
Type 2 diabetes mellitus (DM2) is characterized by excessive hepatic gluconeogenesis, increased insulin resistance and a progressive inability of pancreatic beta cells to produce sufficient insulin. DM2 evolves as a progression from normal glucose tolerance, to impaired glucose tolerance (IGT) to frank diabetes mellitus, reflecting the establishment of insulin resistance and beta cell dysfuncti...
متن کاملCombination lipid therapy in type 2 diabetes.
To the Editor: In the Action to Control Car diovascular Risk in Diabetes (ACCORD) trial (ClinicalTrials.gov number, NCT00000620) report ed on by Ginsberg et al. (April 29 issue),1 the use of fenofibrate in patients with type 2 diabetes mellitus who were receiving simvastatin and who were at high risk for cardiovascular disease great ly reduced triglyceride levels but hardly increased levels ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Practical Diabetes International
سال: 2004
ISSN: 1357-8170,1528-252X
DOI: 10.1002/pdi.687